Collplant Biotechnologies Ltd

NASDAQ CLGN

Data sourced from

and

Daily

Download Data

Collplant Biotechnologies Ltd Price to Book Ratio (P/B) on June 03, 2024: 2.22

Collplant Biotechnologies Ltd Price to Book Ratio (P/B) is 2.22 on June 03, 2024, a -21.50% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Collplant Biotechnologies Ltd 52-week high Price to Book Ratio (P/B) is 3.10 on June 26, 2023, which is 39.60% above the current Price to Book Ratio (P/B).
Collplant Biotechnologies Ltd 52-week low Price to Book Ratio (P/B) is 1.67 on March 06, 2024, which is -24.93% below the current Price to Book Ratio (P/B).
Collplant Biotechnologies Ltd average Price to Book Ratio (P/B) for the last 52 weeks is 2.10.

NASDAQ: CLGN

Collplant Biotechnologies Ltd

CEO	Mr. Yehiel Tal
IPO Date	Jan. 30, 2018
Location	Israel
Headquarters	Weizmann Science Park, Rehovot, Israel, 7670104
Employees	75
Sector	Healthcare
Industry	Biotechnology

Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Key trends